NCT03669367View on ClinicalTrials.gov

EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

June 30, 2022

Study Completion Date

September 30, 2024

Conditions
Palindromic Rheumatism, Wrist
Interventions
DRUG

Abatacept Injection

Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year.

DRUG

hydroxycloroquina

oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months)

Trial Locations (1)

08036

Hospital Clinic i Provincial de Barcelona, Barcelona

All Listed Sponsors
lead

Fundacion Clinic per a la Recerca Biomédica

OTHER

NCT03669367 - EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study) | Biotech Hunter | Biotech Hunter